Laurus Labs on Thursday said the US drug authority USFDA has completed the pre-approval inspection for an API manufactured at its units 1 & 3, at JN Pharma City, Parawada, Visakhapatnam, Andhra Pradesh, with three observations, which are procedural in nature.
“No data integrity issues were observed in the inspection,” it further said. The inspection was carried out from November 18-21.
The stock may remain in focus, as investors will follow further developments.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.